Liver and Spleen Stiffness Measured by 2D-SWE for Diagnosis of Liver Fibrosis in Patients With cACLD
1 other identifier
observational
150
1 country
1
Brief Summary
A observational diagnostic study will be conducted to evaluate the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) for diagnosing liver fibrosis in people with compensated Advanced Chronic Liver Disease (cACLD), and explore the cut-off value of 2D-SWE for diagnosing liver fibrosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2023
CompletedFirst Submitted
Initial submission to the registry
November 15, 2023
CompletedFirst Posted
Study publicly available on registry
November 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedNovember 28, 2023
November 1, 2023
1.2 years
November 15, 2023
November 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Sensitivity of 2D-SWE
True Positive/ (True Positive+False Negative) ×100%
Through study completion, an average of 2 year
Specificity of 2D-SWE
True Negative/ (True Negative+False Positive) ×100%
Through study completion, an average of 2 year
Positive Predictive Value of 2D-SWE
True Positive/ (True Positive+False Positive) ×100%
Through study completion, an average of 2 year
Negative Predictive Value of TE and 2D-SWE
True Negative/ (True Negative+False Negative) ×100%
Through study completion, an average of 2 year
Overall diagnostic performance of TE and 2D-SWE
Measured by the area under the receiver operating characteristic curve (AUROC). The test accuracy level is considered high when the AUROC value is ≥ 0.9.
Through study completion, an average of 2 year
Study Arms (1)
study group
All participants included will be in one study group.
Interventions
Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination. Reference standard: Liver biopsy will be conducted by experienced interventionists and reported by pathologists. There should be a maximum interval of no more than 1 month between the liver biopsy and ultrasound examination, and the length of specimen should be more than 1.0cm.
Eligibility Criteria
Patients with chronic liver disease who visit Fifth Affiliated Hospital, Sun Yat-Sen University will be enrolled from October 2023 to January 2025. Their liver stiffness measured by transient elastography (TE) should be at least 10kPa no previous decompensation symptoms.
You may qualify if:
- Age≥18 years old;
- Chronic liver disease (alcoholic liver disease, chronic hepatitis B, chronic hepatitis C or non-alcoholic fatty liver disease);
- No previous decompensation-related manifestations (such as ascites, gastrointestinal varicose bleeding, hepatic encephalopathy, etc.);
- Informed consent has been signed.
You may not qualify if:
- Hepatocellular carcinoma or other advanced malignant tumor;
- Acute liver disease or ALT≥5×ULN;
- Persistent substance abuse other than alcohol;
- Pregnancy or HIV infection;
- There are contraindications of percutaneous liver biopsy (such as serious abnormality of coagulation function, etc.);
- There are conditions that seriously affect TE and 2D-SWE measurements (such as the intercostal space is too narrow, BMI≥30, etc.);
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Fifth Affiliated Hospital, Sun Yat-sen University
Zhuhai, Guangdong, 519000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xi Liu, PhD
The Fifth Affiliated Hospital, Sun Yat-sen University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 15, 2023
First Posted
November 28, 2023
Study Start
November 1, 2023
Primary Completion
January 1, 2025
Study Completion
January 1, 2025
Last Updated
November 28, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share
The datasets generated during and/or analysed during the current study will be available from the principal investigator on reasonable request.